Pharos IBio Co (XKRX:388870) Net Cash per Share : ₩1,642.87 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Pharos IBio Co's Net Cash per Share for the quarter that ended in Mar. 2024 was ₩1,642.87.

The historical rank and industry rank for Pharos IBio Co's Net Cash per Share or its related term are showing as below:

XKRX:388870' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.87 Med: 7.93 Max: 11.4
Current: 7.88

During the past 5 years, the highest Price-to-Net-Cash Ratio of Pharos IBio Co was 11.40. The lowest was 6.87. And the median was 7.93.

XKRX:388870's Price-to-Net-Cash is ranked worse than
70.57% of 863 companies
in the Biotechnology industry
Industry Median: 3.94 vs XKRX:388870: 7.88

Pharos IBio Co Net Cash per Share Historical Data

The historical data trend for Pharos IBio Co's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Net Cash per Share Chart

Pharos IBio Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

-1,573.17

-3,881.25

-9,453.25

1,578.83

1,869.01

Pharos IBio Co Quarterly Data
	Mar22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Net Cash per Share	Get a 7-Day Free Trial			1,219.09	956.07	2,050.91	1,869.01	1,642.87

Competitive Comparison of Pharos IBio Co's Net Cash per Share

For the Biotechnology subindustry, Pharos IBio Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharos IBio Co's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharos IBio Co's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Pharos IBio Co's Price-to-Net-Cash falls into.

Pharos IBio Co Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Pharos IBio Co's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(25486.759	-	1341.046	-	0)	/	12.919
=	1,869.01

Pharos IBio Co's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

	Net Cash per Share (Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(22356.162	-	1131.91	-	0)	/	12.919
=	1,642.87

Pharos IBio Co (XKRX:388870) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Pharos IBio Co Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharos IBio Co (XKRX:388870) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR

Website

https://www.pharosibio.com

Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co (XKRX:388870) Headlines

No Headlines